Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-ketamine for perioperative depression in breast tumor surgery
ChiCTR2500102621Phase 4Completed
- Sponsor
- First Affiliated Hospital of Xinjiang Medical University
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in major depressive disorder (MDD) and breast neoplasia (2 arms), sponsored by First Affiliated Hospital of Xinjiang Medical University. Primary endpoint: Self-Rating Depression Scale (SDS) score. Started May 2025; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)breast neoplasia
Beyond the preview
Go deeper on ChiCTR2500102621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102621.